HUS1

HUS1
Name	HUS1
Uniprot	Q9H3K2
Organism	Homo sapiens
Length	289 aa
Chromosome	11p15.5

HUS1 HUS1 is a human protein component of the 9-1-1 checkpoint complex involved in DNA damage sensing and repair. It participates in cell cycle checkpoints, modulates ATR-dependent signaling, and contributes to genomic stability in proliferating tissues. HUS1 has been studied across biochemistry, cell biology, and clinical research contexts, including cancer biology, ataxia-telangiectasia studies, and hereditary instability syndromes.

Introduction

HUS1 was identified through genetic and biochemical screens that connected DNA replication stress to checkpoint signaling in mammalian cells, yeast, and Xenopus systems. Early work linked the protein to cell cycle arrest phenotypes described in studies of RAD9 homolog (S. pombe), RAD1 homolog (S. cerevisiae), and the ATR-activating apparatus characterized alongside ATRIP and ATR. Subsequent proteomic and structural studies placed HUS1 within a conserved clamp-like ring required for recruitment of repair factors at sites of stalled replication forks, double-strand breaks characterized in assays used by investigators at institutions such as Cold Spring Harbor Laboratory, Max Planck Institute, and Broad Institute.

Structure and Expression

HUS1 encodes a polypeptide of approximately 289 amino acids that adopts an alpha-helical architecture enabling ring formation with partner subunits. Structural analyses combining cryo-electron microscopy and X-ray crystallography, techniques advanced at facilities like European Synchrotron Radiation Facility and Stanford Synchrotron Radiation Lightsource, revealed interfaces that mediate assembly with RAD9 and RAD1 to form the heterotrimeric 9-1-1 complex. Transcriptomic datasets from consortia including ENCODE, GTEx Project, and The Cancer Genome Atlas demonstrate HUS1 expression across proliferative organs such as bone marrow, testis, and intestinal epithelium, and elevated expression in certain glioblastoma multiforme and breast carcinoma samples. Post-translational modifications detected by mass spectrometry platforms at ProteomeXchange include phosphorylation sites modulated during S-phase and after ionizing radiation exposure, paralleling regulatory patterns reported for proteins like CHK1, CHK2, and PCNA.

Function in DNA Damage Response

HUS1 functions as part of a sensor apparatus that recognizes DNA lesions and replication stress, acting upstream of transducers such as ATR and effectors including p53 and CDC25A. The 9-1-1 complex loaded onto DNA by the RFC-like clamp loader RFC2-5 coordinates recruitment of endonucleases, translesion synthesis polymerases, and homologous recombination factors exemplified by RAD51 and BRCA1. In cellular assays employing agents like hydroxyurea, camptothecin, and ionizing radiation, HUS1 is required for S-phase checkpoint enforcement, fork stabilization, and suppression of chromosomal aberrations detected in cytogenetics laboratories. Biochemical reconstitution experiments performed in systems from groups at Cold Spring Harbor Laboratory and University of Cambridge established that HUS1-mediated signaling shapes ATR substrate specificity and promotes checkpoint recovery through interactions with phosphatases such as PP2A.

Protein Interactions and Complexes

HUS1 forms a heterotrimeric ring with RAD9 and RAD1, analogous to the proliferating cell nuclear antigen clamp; this assembly is essential for localization to sites of damaged DNA alongside clamp loader complexes containing RFC1 and RFC2. Proteomic interaction maps list associations between HUS1 and proteins involved in mismatch repair like MSH2, nucleotide excision factors such as XPA, recombination mediators including MRE11, and scaffold proteins exemplified by MDC1. Functional partnerships extend to chromatin remodelers like SMARCA5 and ubiquitin ligases observed in studies at Massachusetts Institute of Technology and Johns Hopkins University, which implicate HUS1 in ubiquitylation-dependent turnover of checkpoint components. The 9-1-1 complex also collaborates with mediator proteins such as TOPBP1 to potentiate ATR activation in response to single-stranded DNA coated by RPA.

Clinical Significance and Disease Associations

Altered HUS1 expression or function has been implicated in multiple human pathologies. Somatic dysregulation appears in subsets of colorectal carcinoma, ovarian carcinoma, and lung adenocarcinoma specimens profiled by TCGA Research Network, correlating with genomic instability signatures and chemotherapy sensitivity. Germline variants affecting checkpoint genes, including those interacting with HUS1, have been evaluated in relation to hereditary cancer predisposition panels offered by clinical laboratories such as Ambry Genetics and Mayo Clinic Laboratories. Functional deficiency of HUS1 sensitizes cells to PARP inhibitors and DNA-damaging agents used in treatment regimens for breast cancer and ovarian cancer, informing translational studies at centers like Memorial Sloan Kettering Cancer Center. In addition, HUS1 perturbation contributes to phenotypes resembling neurodegenerative disorders studied in cohorts at University College London and Karolinska Institutet, where defective DNA repair pathways converge on neuronal loss seen in conditions such as ataxia-telangiectasia.

Model Organisms and Experimental Studies

Genetic deletion and knockdown of Hus1 orthologs in model systems including Mus musculus, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Xenopus laevis have elucidated conserved checkpoint roles. Conditional Hus1 knockout mice generated at institutions like Harvard Medical School exhibit embryonic lethality or tissue-restricted genomic instability phenotypes, while zebrafish models developed at Scripps Research display developmental defects upon morpholino-mediated depletion. High-throughput chemical screens in yeast and human cell lines performed by laboratories such as Broad Institute identified synthetic lethal interactions between HUS1 deficiency and inhibitors targeting ATR or CHK1, guiding preclinical combination strategies tested at oncology centers including Dana-Farber Cancer Institute.

Category:DNA repair proteins